1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.

2. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405:857-865.

3. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-1671.

4. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. J Am Med Assoc 2001; 286:2270-2279.

5. Kalow W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther 2001; 70:1-4.

6. Brookes AJ. The essence of SNPs. Gene 1999; 234:177-186.

7. Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P. Metabolic polymorphisms and susceptibility to cancer. IARC Sci Publ (148). Lyon: IARC, 1999.

8. Donaldson M. Annual Report of the Chief Medical Officer. London: Department of Health, 2001.

9. Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis—twin concordances for alcoholism and its biological end-points by zygosity among male veterans. Alcohol Clin Exp Res 1981; 5:207-215.

10. Crabb DW. Alcoholic liver disease: new concepts in pathogenesis. In: Suchy FJ, Fitz JG, Maher JJ, eds. Mechanisms of Acute & Chronic Liver Diseases: Implications for Diagnosis, Pathogenesis & Treatment. Boston: American Association for the Study of Liver Diseases, 2002:104-112.

11. Morimoto M, Hagbjork AL, Wan YJY, Fu PC, Clot P, Albano E, Ingelman-Sundberg M, French SW. Modulation of experimental alcohol-induced liver-disease by cytochrome-P450 2E1 inhibitors. Hepatology 1995; 21:1610-1617.

12. Bosron WF, Li T-K. Genetic polymorphism of human liver alcohol and aldehyde dehydro-genases, and their relationship to alcohol metabolism and alcoholism. Hepatology 1986; 6:502-510.

13. Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Alcohol Clin Exp Res 1997; 21:596-601.

14. Day CP, Bashir R, James OFW, Bassendine MF, Crabb DW, Thomasson HR, Li TK, Edenberg HJ. Investigation of the role of polymorphisms at the alcohol and aldehyde dehy-drogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology 1991; 14:798-801.

15. Poupon RE, Nalpas B, Outelle C, Leury B, Ouzigou P, Higueret D. Polymorphism of alcohol-dehydrogenase, alcohol and aldehyde dehydrogenase-activities—implication in alcoholic cirrhosis in white patients. Hepatology 1992; 15:1017-1022.

16. Couzigou P, Fleury B, Roppi A, Assaigne A, Egueret J, Ron A. Genotyping study of alcohol-dehydrogenase class-I polymorphism in French patients with alcoholic cirrhosis. Alcohol Alcohol 1990; 25:623-626.

17. Grove J, Brown ASM, Daly AK, Bassendine MF, James OFW, Day CP. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998; 8:335-342.

18. Borras E, Coutelle C, Rosell A, Fernandez-Muixi F, Broch M, Crosas B, Hjelmqvist L, Lorenzo A, Gutierrez C, Santos M, Szczepanek M, Heilig M, Quttrocchi P, Farres J, Vidal F, Richart C, Mach T, Bogdal J, Jornvall H, Seitz H, Couzigou P, Pares X. Genetic polymorphism of alcohol dehydrogenase in Europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. Hepatology 2000; 31:984-989.

19. Enomoto N, Takase S, Takada N, Takada A. Alcoholic liver-disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes. Hepatology 1991; 13:1071-1075.

20. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)—a review. Alcohol Clin Exp Res 2002; 23:991-1007.

21. Pirmohamed M, Kitteringham NR, Quest LJ, Allott RL, Green VJ, Gilmore IT, Park BK. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 1995; 5:351-357.

22. Wong N, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cyto-chrome P4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53:88-93.

23. KiyosawaK, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.

24. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, ed. Casarett & Doull's Toxicology: The Basic Science of Poisons. Kansas: McGraw-Hill, Inc., 1996:113-186.

Guengerich FP. Epoxide hydrolase: properties and metabolic roles. Rev Biochem Toxicol 1982; 4:5-30.

Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994; 3:421-428.

Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett 2000; 112-113:365-370.

Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Bottelli R, Mondelli MU, Civardi E, Silini EM. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002; 36:195-201.

Hsu IC, Metcalf RA, Sun T, Wesh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 1991; 350:427-428. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429-431. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia X-L, Baffoe-Bonnie A, Ofori-Adjei D, Chen G-C, London WT, Shen F-M, Buetow KH. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92:2384-2387. Brockmoller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 1993; 53:1004-1011.

Farrokyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001; 36:2-15.

Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161:5733-5744.

Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002; 160:739-751.

Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738.

Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.

Schwab M, Schaeffeler E, MarX C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124:26-33.

Farrell JR, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PWN, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterol-ogy 2000; 118:279-288.

Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123:132-142. Aithal GP, Hoffman BJ. Steering azathioprine safely: lessons from pharmacogenetics. Am J Gastroenterol 2001; 96:3002-3003.

Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyl transferase. Drug Metab Dispos 2001; 29:601-605.

Weinshilboum R, Sladck SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.

44. Krynetski EY, Schuetz JD, Galpin AJ, Pui C-H, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Nat Acad Sci USA 1995; 92:949-953.

45. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennaed L, Wieben E, Weinshilboum R. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of common polymorphism. DNA Cell Biol 1996; 15:17-30.

46. Tai -L, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskala NF, Evans WE. Thiopurine S-methyltransferase deficiency. Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.

47. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Phar-macogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.

48. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48:642-646.

49. Lowry PW, Franklin CL, Weaver AL, Gennett Pike M, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49:665-670.

50. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16:389-398.

51. Colombel J-F, Ferrari N, Debuysere H, Marteau P, Gendre J-P, Bonaz B, Soule J-C, Modigliani R, Groupe d'Etudes Therapeutique des Affections Inflammataires Digestives (GETAID), Touze Y, Catala P, Libersa C, Broly F. Genotyping analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 119:1025-1030.

52. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915.

53. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.

54. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598.

55. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprozole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70:484-492.

56. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashina M, Xino F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15:1929-1937.

57. Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, Kodama F, Okumura K, Kasuga M. Sufficient effect of 1-week omeprazole and amoxacillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999; 34:80-83.

58. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11:341-348.

59. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP1C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69:158-168.

Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Lida T, Sato Y, Kajimura M, Futami H, Takayanagi S, YamadaM, Ohashi K, Ishizaki T, Hanai H. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprozole. Clin Pharmacol Ther 2002; 72:453-460.

Drews J, Ryser S. The role of innovation in drug development. Nat Biotech 1997; 15:13181319.

Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 2002; 123:425-432.

von der Ohe MR, Harison RB, Camilleri M. Serotoninergic mediation of postprandial colonic tonic and phasic response in humans. Gut 1994; 35:536-541.

Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355:1035-1040.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AW. A randomized controlled clinical trial of serotonin type 3 receptor antagonist aloserton in women with diarrhea predominant irritable bowel syndrome. Arch Intern Med 2001; 161:1733-1740.

Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621-2624. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527-1531. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhoea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425-432.

Herion D, Hoofnagle JH. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 1997; 25:769-771.

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl J Med 1996; 334:77-81.

Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima M, Ikeda K, Kumada H. Pretreatment virus load and multiple amino acid substitution in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25:745-749. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C. Analysis of genotypes and aminoacid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25:750-753.

Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology 2002; 36:177-185.

Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno, de Mesquita HB, Ghadirian P, Jain M, Przewozniak K, Baghurst P, Moerman, CJ, Simard A, Howe GR, McMichael AJ, Hsieh CC, Walker AM. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89:1132-1138.

Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998; 279:1200-1205. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000; 356:1587-1591.

77. Park B, Pirmohamed M, Kitteringham N. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969-988.

78. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. Br Med J 2000; 320:1036.

79. Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47:209 -216.

80. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Group. J Am Med Assoc 1997; 277:307-311.

81. Creemers GJ, Lund B, Verweij J. Tropoisomerase I inhibitors topotecan and irenotecan. Cancer Treat Rev 1994; 20:73-96.

82. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 2000; 343: 905-914.

83. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist 2001; 6:66-80.

84. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86:101-110.

85. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191.

86. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991; 21:1159-1169.

87. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyl-transferases and irinotecan toxicity. Mol Pharmacol 2002; 62:446-450.

88. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic rate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54:3723-3725.

89. Iyer L, Hall D, Das S, Mortell MA, Radmirez J, Kim S, Di Rienzo, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-582.

90. Gagne J-F, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.

91. Strassburg CP, Manns MP. Jaundice, genes and promoters. J Hepatol 2000; 33:476-479.

92. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-Glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships in serum bilirubin concentrations. Pharmacogenetics 1999; 9:341-349.

93. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.

94. Strassburg CP, Nguyen N, Manns MP, Tukey RH. UDP-glucuronosyl-transferase activity in human liver and colon. Gastroenterology 1999; 116:149-160.

95. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 2002; 93:591 -597.

96. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. New Engl J Med 1999; 341:1368-1378.

97. Lumley C. Clinical toxicity: could it have been predicted? Pre-marketing experience. In: Lumley CE, Walker SR, eds. Animal Toxicity Studies. Their Relevance to Man. Lancaster: Quay Publishing, 1990:49-57.

Aithal GP, Day CP. Hepatic adverse drug reactions. In: Andrews EB, Mann RD, eds. Phar-macovigilance. 1st ed. Chichester: John Wiley & Sons Ltd, 2002:459-474. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36:451-455.

Spriet-Pourra C, Auriche M. Drug withdrawal from sales. 2nd ed. Richmond: PJB Publications Ltd, 1994.

Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25:1057-1064. Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, Elias E. A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxy-lation. J Hepatol 1988; 7:72-78.

Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994; 21:1075-1079. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31:201-206.

Huang Y-S, Chern H-D, Su W-J, Wu J-C, Lai S-L, Yang S-Y, Chang F-Y, Lee S-D. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883-889.

Hwang SJ, Wu Jc, Lee CN, Yen FS, Lu CJ, Lin TP, Lee SD. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12:87-91.

Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6:295-298. Acharya SK, Dasarathy S, Kumer TL, Shuma S, Prasanna KS, Tandon A, Sreenivas V, Nijhawan S, Panda SK, Nanda SK, Irshad M, Joshi YK, Duttagupta S, Tandon RK, Tandon BN. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23:1448-1455.

Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Cuesta FSDL. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123-130. Spahr L, Villeneuve J-P, Dufresne M-P, Tasse D, Bui B, Willems B, Fenyves D, Pomier-Layrargues G. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44:739-742.

Littlewood ER, Barrison IG, Murray-Lyon IM, Paradinas FJ. Cholangiocarcinoma and oral contraceptives. Lancet 1980; 1:310-311.

Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84:181-192.

Ellard GA, Gammon PT. Pharmacokinetics of isoniazid in humans. J Pharmacokinet Biopharm 1976; 4:83-113.

Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazine metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235: 566-570.

Scales MD, Timbrell JA. Studies on hydrazine hepatotoxicity. 1. Pathological findings. J Toxicol Environ Health 1982; 10:941-953.

Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampicin. Am Rev Resp Dis 1986; 133:1072-1075.

Blum M, Grant DM, McBride W, Heim H, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990; 9:193-203.

118. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55:3531-3536.

119. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl J Med 1997; 337:725-733.

120. Kaul DR, Cinti SK, Carver PL, Kazanjian PH. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19:281-298.

121. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, Lin JH. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996; 24:1389-1394.

122. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98:12671-12676.

123. Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, Fromenty, Benhamou JP, Pessayre D. Possible role of HLA in hepatotoxicity. an exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20:336-342.

124. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP. Hepatitis associated with amoxicillin-clavulanic acid combination: report of 15 cases. Gut 1992; 33:368-371.

125. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxycillin and clavulanic acid. Arch Intern Med 1996; 156:1327-1332.

126. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47:717-720.

127. Hautekeete ML, Horsmans Y, Waeyenberge CV, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PSH, Rahier J, Geubel AP. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117:1181-1186.

128. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-499.

129. RischNJ. Searching for genetic determinants in the new millenium. Nature 2000; 405: 847-856.

130. Rodriguez LAG, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with non-steroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154:311-316.

131. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity. Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22:820-827.

132. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 1993; 52:29-34.

133. Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 1996; 51:79-85.

134. Bort R, Mace K, Boobis A, Gomez-Lechon M-J, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58:787-796.

135. Shen S, Marchick MR, Davis MR, Doss GA, Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 1999; 12:214-222.

136. Tang W, Stearns RA, Wang RW, Chiu S-HL, Baillie TA. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999; 12:192-199.

137. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001; 61:49-53.

138. Kretz-Rommel A, Boelsterli UA. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 1993; 120:155-161.

139. Kretz-Rommel A, Boelsterli UA. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol Pharmacol 1994; 45:237-244.

140. Hargus SJ, Amouzedeh HR, Pumford NR, Myers TG, McCoy SC, Pohl LR. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1994; 7:575-582.

141. Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-T cells from diclofenac-immunised mice against cultured syngenic hepatocytes exposed to diclofenac. Hepatology 1995; 22:213-222.

142. Aithal GP. Hepatotoxicity: accuracy of diagnosis, long term outcome and the role of genetic polymorphism in drug metabolism and adverse drug reactions. PhD dissertation, University of Newcastle, Newcastle upon Tyne 2000.

143. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10:511-518.

144. Aithal GP, Leathart JB, Dang TS, Day CP, Daly AK. Association of UDP-glucuronyltransfer-ase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity (abstr). Hepatology 2002; 36(4):333A.

145. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Coldwell J, Day CP. Hepatic adults, circulating antibodies and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39:1430-1440.

146. Lander ES, Schork NJ. Genetic dissection of complex traits. New Engl J Med 2002; 265:2037-2048.

147. Schreiber S, Hampe J, Eickhoff H, Lehrach H. Functional genomics in gastroenterology. Gut 2000; 47:601-607.

148. Lander ES. Array of hope. Nat Genet 1999; 21:3-4.

149. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355:1358-1361.

Beat The Battle With The Bottle

Beat The Battle With The Bottle

Alcoholism is something that can't be formed in easy terms. Alcoholism as a whole refers to the circumstance whereby there's an obsession in man to keep ingesting beverages with alcohol content which is injurious to health. The circumstance of alcoholism doesn't let the person addicted have any command over ingestion despite being cognizant of the damaging consequences ensuing from it.

Get My Free Ebook

Post a comment